BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29049752)

  • 1. Cytomegalovirus infection in living-donor and cadaveric lung transplantations.
    Ohata K; Chen-Yoshikawa TF; Takahashi K; Aoyama A; Motoyama H; Hijiya K; Hamaji M; Menju T; Sato T; Sonobe M; Takakura S; Date H
    Interact Cardiovasc Thorac Surg; 2017 Nov; 25(5):710-715. PubMed ID: 29049752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft dysfunction immediately after reperfusion predicts short-term outcomes in living-donor lobar lung transplantation but not in cadaveric lung transplantation.
    Mizota T; Miyao M; Yamada T; Sato M; Aoyama A; Chen F; Date H; Fukuda K
    Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):314-20. PubMed ID: 26705301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients†.
    Date H; Sato M; Aoyama A; Yamada T; Mizota T; Kinoshita H; Handa T; Tanizawa K; Chin K; Minakata K; Chen F
    Eur J Cardiothorac Surg; 2015 Jun; 47(6):967-72; discussion 972-3. PubMed ID: 25228745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.
    Hammond SP; Martin ST; Roberts K; Gabardi S; Fuhlbrigge AL; Camp PC; Goldberg HJ; Marty FM; Baden LR
    Transpl Infect Dis; 2013 Apr; 15(2):163-70. PubMed ID: 23230972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
    Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
    Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus (CMV) excretion as a factor in the severity of CMV disease in kidney and simultaneous kidney and pancreas transplantation.
    Pouteil-Noble C; Ecochard R; Bosshard S; Lacavalerie B; Donia A; Landrivon G; Tardy JC; Dubernard JM; Aymard M; Touraine JL
    Transpl Int; 1992; 5 Suppl 1():S26-9. PubMed ID: 14621724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E; Lesnick T; Kremers W; Kennedy CC; Razonable RR
    Clin Transplant; 2016 Mar; 30(3):270-8. PubMed ID: 26701733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.
    Ranganathan K; Worley S; Michaels MG; Arrigan S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet SC; Faro A; Danziger-Isakov L
    J Heart Lung Transplant; 2009 Oct; 28(10):1050-6. PubMed ID: 19782286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of cytomegalovirus infection after pancreas transplantation.
    Parsaik AK; Bhalla T; Dong M; Rostambeigi N; Dierkhising RA; Dean P; Abraham R; Prieto M; Kremers WK; Razonable RR; Kudva YC
    Transplantation; 2011 Nov; 92(9):1044-50. PubMed ID: 21904269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
    Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
    Kruger RM; Paranjothi S; Storch GA; Lynch JP; Trulock EP
    J Heart Lung Transplant; 2003 Jul; 22(7):754-63. PubMed ID: 12873543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignancies after living-donor and cadaveric lung transplantations in Japanese patients.
    Tanaka S; Chen-Yoshikawa TF; Yamada T; Hijiya K; Motoyama H; Aoyama A; Date H
    Surg Today; 2016 Dec; 46(12):1415-1419. PubMed ID: 26983711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quantitative monitoring of blood cytomegalovirus after allogeneic hematopoietic stem cell transplantation and its clinical significance].
    Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Li Y; Liang ZY; Cen XN; Ren HY
    Zhonghua Nei Ke Za Zhi; 2012 May; 51(5):371-5. PubMed ID: 22883336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
    Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.